List of Chapters/Sections(Table Of Content)
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2030)
1.4.2 East Asia Market States and Outlook (2023-2030)
1.4.3 Europe Market States and Outlook (2023-2030)
1.4.4 South Asia Market States and Outlook (2023-2030)
1.4.5 Southeast Asia Market States and Outlook (2023-2030)
1.4.6 Middle East Market States and Outlook (2023-2030)
1.4.7 Africa Market States and Outlook (2023-2030)
1.4.8 Oceania Market States and Outlook (2023-2030)
1.4.9 South America Market States and Outlook (2023-2030)
1.5 Global Inactivated Influenza Vaccine Market Size Analysis from 2023 to 2030
1.5.1 Global Inactivated Influenza Vaccine Market Size Analysis from 2023 to 2030 by Consumption Volume
1.5.2 Global Inactivated Influenza Vaccine Market Size Analysis from 2023 to 2030 by Value
1.5.3 Global Inactivated Influenza Vaccine Price Trends Analysis from 2023 to 2030
1.6 COVID-19 Outbreak: Inactivated Influenza Vaccine Industry Impact
Chapter 2 Global Inactivated Influenza Vaccine Competition by Types, Applications, and Top Regions and Countries
2.1 Global Inactivated Influenza Vaccine (Volume and Value) by Type
2.1.1 Global Inactivated Influenza Vaccine Consumption and Market Share by Type (2017-2022)
2.1.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Type (2017-2022)
2.2 Global Inactivated Influenza Vaccine (Volume and Value) by Application
2.2.1 Global Inactivated Influenza Vaccine Consumption and Market Share by Application (2017-2022)
2.2.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Application (2017-2022)
2.3 Global Inactivated Influenza Vaccine (Volume and Value) by Regions
2.3.1 Global Inactivated Influenza Vaccine Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Inactivated Influenza Vaccine Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Inactivated Influenza Vaccine Consumption by Regions (2017-2022)
4.2 North America Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
4.10 South America Inactivated Influenza Vaccine Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Inactivated Influenza Vaccine Market Analysis
5.1 North America Inactivated Influenza Vaccine Consumption and Value Analysis
5.1.1 North America Inactivated Influenza Vaccine Market Under COVID-19
5.2 North America Inactivated Influenza Vaccine Consumption Volume by Types
5.3 North America Inactivated Influenza Vaccine Consumption Structure by Application
5.4 North America Inactivated Influenza Vaccine Consumption by Top Countries
5.4.1 United States Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
5.4.2 Canada Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
5.4.3 Mexico Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 6 East Asia Inactivated Influenza Vaccine Market Analysis
6.1 East Asia Inactivated Influenza Vaccine Consumption and Value Analysis
6.1.1 East Asia Inactivated Influenza Vaccine Market Under COVID-19
6.2 East Asia Inactivated Influenza Vaccine Consumption Volume by Types
6.3 East Asia Inactivated Influenza Vaccine Consumption Structure by Application
6.4 East Asia Inactivated Influenza Vaccine Consumption by Top Countries
6.4.1 China Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
6.4.2 Japan Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
6.4.3 South Korea Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 7 Europe Inactivated Influenza Vaccine Market Analysis
7.1 Europe Inactivated Influenza Vaccine Consumption and Value Analysis
7.1.1 Europe Inactivated Influenza Vaccine Market Under COVID-19
7.2 Europe Inactivated Influenza Vaccine Consumption Volume by Types
7.3 Europe Inactivated Influenza Vaccine Consumption Structure by Application
7.4 Europe Inactivated Influenza Vaccine Consumption by Top Countries
7.4.1 Germany Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.2 UK Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.3 France Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.4 Italy Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.5 Russia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.6 Spain Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.7 Netherlands Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.8 Switzerland Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
7.4.9 Poland Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 8 South Asia Inactivated Influenza Vaccine Market Analysis
8.1 South Asia Inactivated Influenza Vaccine Consumption and Value Analysis
8.1.1 South Asia Inactivated Influenza Vaccine Market Under COVID-19
8.2 South Asia Inactivated Influenza Vaccine Consumption Volume by Types
8.3 South Asia Inactivated Influenza Vaccine Consumption Structure by Application
8.4 South Asia Inactivated Influenza Vaccine Consumption by Top Countries
8.4.1 India Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
8.4.2 Pakistan Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Inactivated Influenza Vaccine Market Analysis
9.1 Southeast Asia Inactivated Influenza Vaccine Consumption and Value Analysis
9.1.1 Southeast Asia Inactivated Influenza Vaccine Market Under COVID-19
9.2 Southeast Asia Inactivated Influenza Vaccine Consumption Volume by Types
9.3 Southeast Asia Inactivated Influenza Vaccine Consumption Structure by Application
9.4 Southeast Asia Inactivated Influenza Vaccine Consumption by Top Countries
9.4.1 Indonesia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.2 Thailand Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.3 Singapore Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.4 Malaysia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.5 Philippines Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.6 Vietnam Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
9.4.7 Myanmar Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 10 Middle East Inactivated Influenza Vaccine Market Analysis
10.1 Middle East Inactivated Influenza Vaccine Consumption and Value Analysis
10.1.1 Middle East Inactivated Influenza Vaccine Market Under COVID-19
10.2 Middle East Inactivated Influenza Vaccine Consumption Volume by Types
10.3 Middle East Inactivated Influenza Vaccine Consumption Structure by Application
10.4 Middle East Inactivated Influenza Vaccine Consumption by Top Countries
10.4.1 Turkey Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.3 Iran Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.5 Israel Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.6 Iraq Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.7 Qatar Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.8 Kuwait Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
10.4.9 Oman Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 11 Africa Inactivated Influenza Vaccine Market Analysis
11.1 Africa Inactivated Influenza Vaccine Consumption and Value Analysis
11.1.1 Africa Inactivated Influenza Vaccine Market Under COVID-19
11.2 Africa Inactivated Influenza Vaccine Consumption Volume by Types
11.3 Africa Inactivated Influenza Vaccine Consumption Structure by Application
11.4 Africa Inactivated Influenza Vaccine Consumption by Top Countries
11.4.1 Nigeria Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
11.4.2 South Africa Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
11.4.3 Egypt Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
11.4.4 Algeria Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
11.4.5 Morocco Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 12 Oceania Inactivated Influenza Vaccine Market Analysis
12.1 Oceania Inactivated Influenza Vaccine Consumption and Value Analysis
12.2 Oceania Inactivated Influenza Vaccine Consumption Volume by Types
12.3 Oceania Inactivated Influenza Vaccine Consumption Structure by Application
12.4 Oceania Inactivated Influenza Vaccine Consumption by Top Countries
12.4.1 Australia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
12.4.2 New Zealand Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 13 South America Inactivated Influenza Vaccine Market Analysis
13.1 South America Inactivated Influenza Vaccine Consumption and Value Analysis
13.1.1 South America Inactivated Influenza Vaccine Market Under COVID-19
13.2 South America Inactivated Influenza Vaccine Consumption Volume by Types
13.3 South America Inactivated Influenza Vaccine Consumption Structure by Application
13.4 South America Inactivated Influenza Vaccine Consumption Volume by Major Countries
13.4.1 Brazil Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.2 Argentina Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.3 Columbia Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.4 Chile Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.5 Venezuela Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.6 Peru Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
13.4.8 Ecuador Inactivated Influenza Vaccine Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Inactivated Influenza Vaccine Business
14.1 CSL Limited
14.1.1 CSL Limited Company Profile
14.1.2 CSL Limited Inactivated Influenza Vaccine Product Specification
14.1.3 CSL Limited Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 GSK
14.2.1 GSK Company Profile
14.2.2 GSK Inactivated Influenza Vaccine Product Specification
14.2.3 GSK Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Sanofi Pasteur
14.3.1 Sanofi Pasteur Company Profile
14.3.2 Sanofi Pasteur Inactivated Influenza Vaccine Product Specification
14.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Viatris
14.4.1 Viatris Company Profile
14.4.2 Viatris Inactivated Influenza Vaccine Product Specification
14.4.3 Viatris Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Hualan Biological
14.5.1 Hualan Biological Company Profile
14.5.2 Hualan Biological Inactivated Influenza Vaccine Product Specification
14.5.3 Hualan Biological Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 AstraZeneca
14.6.1 AstraZeneca Company Profile
14.6.2 AstraZeneca Inactivated Influenza Vaccine Product Specification
14.6.3 AstraZeneca Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Sinovac Biotech
14.7.1 Sinovac Biotech Company Profile
14.7.2 Sinovac Biotech Inactivated Influenza Vaccine Product Specification
14.7.3 Sinovac Biotech Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Aleph Biomedical
14.8.1 Aleph Biomedical Company Profile
14.8.2 Aleph Biomedical Inactivated Influenza Vaccine Product Specification
14.8.3 Aleph Biomedical Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Abbott Laboratories
14.9.1 Abbott Laboratories Company Profile
14.9.2 Abbott Laboratories Inactivated Influenza Vaccine Product Specification
14.9.3 Abbott Laboratories Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Novartis International
14.10.1 Novartis International Company Profile
14.10.2 Novartis International Inactivated Influenza Vaccine Product Specification
14.10.3 Novartis International Inactivated Influenza Vaccine Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Inactivated Influenza Vaccine Market Forecast (2023-2030)
15.1 Global Inactivated Influenza Vaccine Consumption Volume, Revenue and Price Forecast (2023-2030)
15.1.1 Global Inactivated Influenza Vaccine Consumption Volume and Growth Rate Forecast (2023-2030)
15.1.2 Global Inactivated Influenza Vaccine Value and Growth Rate Forecast (2023-2030)
15.2 Global Inactivated Influenza Vaccine Consumption Volume, Value and Growth Rate Forecast by Region (2023-2030)
15.2.1 Global Inactivated Influenza Vaccine Consumption Volume and Growth Rate Forecast by Regions (2023-2030)
15.2.2 Global Inactivated Influenza Vaccine Value and Growth Rate Forecast by Regions (2023-2030)
15.2.3 North America Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.4 East Asia Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.5 Europe Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.6 South Asia Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.7 Southeast Asia Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.8 Middle East Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.9 Africa Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.10 Oceania Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.11 South America Inactivated Influenza Vaccine Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.3 Global Inactivated Influenza Vaccine Consumption Volume, Revenue and Price Forecast by Type (2023-2030)
15.3.1 Global Inactivated Influenza Vaccine Consumption Forecast by Type (2023-2030)
15.3.2 Global Inactivated Influenza Vaccine Revenue Forecast by Type (2023-2030)
15.3.3 Global Inactivated Influenza Vaccine Price Forecast by Type (2023-2030)
15.4 Global Inactivated Influenza Vaccine Consumption Volume Forecast by Application (2023-2030)
15.5 Inactivated Influenza Vaccine Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
